Anticoagulation in Patients With Venous Thromboembolism and Cancer

VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04618913

Acronym

VICTORIE

Enrollment

Registered

2020-11-06

Start date

2020-12-14

Completion date

2026-04-06

Last updated

2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Embolism

Keywords

Venous thromboembolism, Eliquis, Neoplasms, Anti-Coagulation

Brief summary

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Interventions

DRUGApixaban

Anticoagulant

DRUGRivaroxaban

Anticoagulant

DRUGEdoxaban

Edoxaban

DRUGDabigatran

Dabigatran

DRUGVKA

Vitamin K antagonist

DRUGLMWH

Low Molecular Weight Heparin

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* A VTE diagnosis * Active cancer or history of cancer * Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH * Age ≥ 18 years at the date of index VTE (Venous thromboembolic)

Exclusion criteria

* Prior VTE diagnosis * Diagnosis of prior atrial fibrillation * Inferior Vena Cava (IVC) filter * Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed. * Pregnancy * More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date. * Patients with less than one day of follow up

Design outcomes

Primary

Measure	Time frame	Description
Recurrence of Thromboembolism	6 Months after treatment began as early as 1/1/2013	The follow-up period during which outcome events of interest will be identified will run from the day after the index date until the end of the data collection or death, whichever occurs first. As data are updated at different times and frequencies in the different study countries, the date of the end of data collection will be determined after the relevant permissions have been acquired from the respective authorities.

Countries

United Kingdom

Contacts

STUDY_DIRECTORPfizer CT.gov Call Center

Pfizer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026